Bone turnover markers in the management of CKD-associated osteoporosis - a European consensus - PubMed
4 days ago
- #chronic kidney disease
- #bone turnover markers
- #CKD-associated osteoporosis
- Bone turnover abnormalities in CKD contribute to bone fragility, leading to the term CKD-associated osteoporosis.
- KDIGO emphasizes the role of bone turnover markers (BTM) in evaluating and managing bone fragility in CKD.
- Current guidelines lack specific treatment targets for bone turnover in CKD-associated osteoporosis.
- This consensus provides recommendations for using BTM in managing CKD-associated osteoporosis.
- Bone-specific alkaline phosphatase and tartrate-resistant acid phosphatase isoform 5b are reliable diagnostic tools in CKD.
- Intact N-terminal telopeptide of type I collagen is also usable in CKD.
- The consensus outlines methodological considerations and clinical uses of BTM in risk prediction, therapy choice, and treatment evaluation.
- Specific diagnostic ranges for bone turnover abnormalities are provided.
- Future research should focus on integrating BTM with other diagnostic tools and establishing treatment targets.